What is Omniab Inc share price today?

Omniab Inc (OABI) share price today is {{live_price}}.

Can Indians buy Omniab Inc shares?

Yes, Indians can invest in the Omniab Inc (OABI) from India. With INDmoney, you can buy Omniab Inc at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Omniab Inc at zero transaction cost.

How can I buy Omniab Inc shares from India?

It is very easy to buy Omniab Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Omniab Inc be purchased?

Yes, you can buy fractional shares of Omniab Inc with INDmoney app.

What are the documents required to start investing in Omniab Inc stocks?

To start investing in Omniab Inc, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Omniab Inc

Today’s highest price of Omniab Inc (OABI) is {{1_rba_end}}. Today’s lowest price of Omniab Inc (OABI) is {{1_rba_st}}.

What is today's market capitalisation of Omniab Inc

Today's market capitalisation of Omniab Inc OABI is 480.9M

What is the 52 Week High and Low Range of Omniab Inc

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Omniab Inc is down from its 52 Week High?

Omniab Inc (OABI) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Omniab Inc is up from its 52 Week low?

Omniab Inc (OABI) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Omniab Inc?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Omniab Inc

Mr. Matthew W. Foehr is the current Chief Executive Officer (CEO) of Omniab Inc.

Home>
US Stocks>
Omniab Inc

Omniab Inc (OABI)

$3.93

-0.14

(-3.44%)▲

Market is closed - opens 7 PM, 04 Oct 2024

Performance

$3.92
$4.09
$3.93
0.25%
Downside
Day's Volatility :4.16%
Upside
3.91%
$3.56
$6.72
$3.93
9.41%
Downside
52 Weeks Volatility :46.98%
Upside
41.47%

Returns

Period	Omniab Inc	Index (Russel 2000)
3 Months	2.88%	0.0%
6 Months	-26.54%	0.0%
1 Year	-23.39%	0.0%
3 Years	63.07%	-20.2%

Highlights

Market Capitalization	480.9M
Book Value	$2.49
Earnings Per Share (EPS)	-0.62
Wall Street Target Price	10.0

Profit Margin	-287.29%
Operating Margin TTM	-247.29%

Return On Assets TTM	-13.95%
Return On Equity TTM	-19.87%

Revenue TTM	21.7M
Revenue Per Share TTM	0.22
Quarterly Revenue Growth YOY	9.6%
Gross Profit TTM	59.1M
EBITDA	-62.0M
Diluted Eps TTM	-0.62
Quarterly Earnings Growth YOY	0.0

EPS Estimate Current Year	-0.57
EPS Estimate Next Year	-0.38
EPS Estimate Current Quarter	-0.17
EPS Estimate Next Quarter	-0.15

Analyst Recommendation

Buy

92%Buy

7%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Omniab Inc(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 154.45%

Current $3.93

Target $10.00

Company Financials

	FY19	Y/Y Change
Revenue	18.3M	-
Net Income	-13.6M	-
Net Profit Margin	-74.18%	-

	FY20	Y/Y Change
Revenue	23.3M	↑ 27.02%
Net Income	-17.6M	↑ 29.2%
Net Profit Margin	-75.46%	↓ 1.28%

	FY21	Y/Y Change
Revenue	34.7M	↑ 49.34%
Net Income	-27.0M	↑ 54.02%
Net Profit Margin	-77.82%	↓ 2.36%

	FY22	Y/Y Change
Revenue	59.1M	↑ 70.02%
Net Income	-22.3M	↓ 17.41%
Net Profit Margin	-37.8%	↑ 40.02%

	FY23	Y/Y Change
Revenue	34.2M	↓ 42.17%
Net Income	-50.6M	↑ 126.65%
Net Profit Margin	-148.16%	↓ 110.36%

	Q1 FY23	Q/Q Change
Revenue	16.9M	↓ 52.13%
Net Income	-6.1M	↓ 189.44%
Net Profit Margin	-36.05%	↓ 55.35%

	Q2 FY23	Q/Q Change
Revenue	6.9M	↓ 58.95%
Net Income	-14.7M	↑ 141.44%
Net Profit Margin	-212.04%	↓ 175.99%

	Q3 FY23	Q/Q Change
Revenue	5.5M	↓ 21.15%
Net Income	-15.7M	↑ 6.86%
Net Profit Margin	-287.35%	↓ 75.31%

	Q4 FY23	Q/Q Change
Revenue	4.8M	↓ 11.96%
Net Income	-14.1M	↓ 10.71%
Net Profit Margin	-291.44%	↓ 4.09%

	Q1 FY24	Q/Q Change
Revenue	3.8M	↓ 21.17%
Net Income	-19.0M	↑ 34.92%
Net Profit Margin	-498.84%	↓ 207.4%

	Q2 FY24	Q/Q Change
Revenue	7.6M	↑ 100.32%
Net Income	-13.6M	↓ 28.11%
Net Profit Margin	-179.03%	↑ 319.81%

	FY19	Y/Y Change
Total Assets	262.3M	-
Total Liabilities	44.1M	-

	FY20	Y/Y Change
Total Assets	295.4M	↑ 12.6%
Total Liabilities	59.8M	↑ 35.59%

	FY21	Y/Y Change
Total Assets	304.5M	↑ 3.08%
Total Liabilities	70.2M	↑ 17.24%

	FY22	Y/Y Change
Total Assets	421.2M	↑ 38.34%
Total Liabilities	79.8M	↑ 13.8%

	FY23	Y/Y Change
Total Assets	402.0M	↓ 4.56%
Total Liabilities	87.4M	↑ 9.47%

	Q1 FY23	Q/Q Change
Total Assets	413.0M	↓ 1.94%
Total Liabilities	72.2M	↓ 9.52%

	Q2 FY23	Q/Q Change
Total Assets	405.2M	↓ 1.89%
Total Liabilities	71.4M	↓ 1.12%

	Q3 FY23	Q/Q Change
Total Assets	391.7M	↓ 3.34%
Total Liabilities	67.2M	↓ 5.98%

	Q4 FY23	Q/Q Change
Total Assets	402.0M	↑ 2.62%
Total Liabilities	87.4M	↑ 30.14%

	Q1 FY24	Q/Q Change
Total Assets	352.6M	↓ 12.3%
Total Liabilities	51.2M	↓ 41.46%

	Q2 FY24	Q/Q Change
Total Assets	337.3M	↓ 4.34%
Total Liabilities	43.1M	↓ 15.79%

	FY19	Y/Y Change
Operating Cash Flow	-5.2M	-
Investing Cash Flow	-12.1M	-
Financing Cash Flow	17.3M	-

	FY20	Y/Y Change
Operating Cash Flow	3.6M	↓ 169.66%
Investing Cash Flow	-27.0M	↑ 123.07%
Financing Cash Flow	23.4M	↑ 35.11%

	FY21	Y/Y Change
Operating Cash Flow	-5.7M	↓ 256.73%
Investing Cash Flow	-4.0M	↓ 85.08%
Financing Cash Flow	9.7M	↓ 58.49%

	FY22	Y/Y Change
Operating Cash Flow	-3.6M	↓ 36.76%
Investing Cash Flow	-73.3M	↑ 1721.44%
Financing Cash Flow	110.7M	↑ 1041.99%

	Q1 FY23	Q/Q Change
Operating Cash Flow	27.7M	↓ 1138.22%
Investing Cash Flow	-37.2M	↓ 38.25%
Financing Cash Flow	-1.0M	↓ 100.95%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-10.0M	↓ 136.2%
Investing Cash Flow	7.8M	↓ 120.93%
Financing Cash Flow	478.0K	↓ 145.74%

Technicals Summary

Sell

Neutral

Buy

Omniab Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Omniab Inc	-3.91%	-26.54%	-23.39%	63.07%	63.07%
Regeneron Pharmaceuticals, Inc.	-13.97%	8.28%	24.49%	82.67%	258.6%
Novo Nordisk A/s	-14.46%	-7.16%	29.25%	137.43%	348.48%
Alnylam Pharmaceuticals, Inc.	8.65%	77.93%	59.32%	38.21%	249.95%
Vertex Pharmaceuticals Incorporated	-5.23%	12.26%	28.5%	155.67%	163.05%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Omniab Inc	NA	NA	NA	-0.57	-0.2	-0.14	NA	2.49
Regeneron Pharmaceuticals, Inc.	27.55	27.55	1.42	45.05	0.17	0.08	NA	261.41
Novo Nordisk A/s	38.7	38.7	1.75	3.41	0.89	0.23	0.01	25.24
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-2.49	-15.01	0.02	NA	-0.02
Vertex Pharmaceuticals Incorporated	32.84	NA	0.55	0.32	-0.03	0.13	NA	57.26

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Omniab Inc	Buy	$480.9M	63.07%	NA	-287.29%
Regeneron Pharmaceuticals, Inc.	Buy	$114.7B	258.6%	27.55	32.04%
Novo Nordisk A/s	Buy	$518.0B	348.48%	38.7	34.84%
Alnylam Pharmaceuticals, Inc.	Buy	$34.9B	249.95%	NA	-3.11%
Vertex Pharmaceuticals Incorporated	Buy	$119.3B	163.05%	32.84	-4.74%

Insights on Omniab Inc

Increasing Revenue
Revenue is up for the last 2 quarters, 3.80M → 7.61M (in $), with an average increase of 50.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -18.96M → -13.63M (in $), with an average increase of 39.1% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.3% return, outperforming this stock by 82.7%